Anteris Technologies Global Corp. 8-K

What Happened
Anteris Technologies Global Corp. announced on May 22, 2026 that it entered into a Sales Agreement with TD Securities (USA) LLC (TD Cowen) that allows the company to offer and sell, from time to time at its discretion, up to $250,000,000 of its common stock through TD Cowen as agent or principal. The offering will be conducted as an “at-the-market” (ATM) offering under the company’s effective Form S-3 shelf registration (File No. 333-292565). The company filed a related prospectus supplement with the SEC on May 22, 2026.

Key Details

• Aggregate offering size: up to $250,000,000 of common stock.
• Sales agent fee: TD Cowen will receive 3.0% of gross proceeds on sales where it acts as sales agent.
• Use of proceeds: primarily for development of the DurAVR® Transcatheter Heart Valve System; remainder for working capital and general corporate purposes.
• Agreement terms: either party may terminate with 10 days’ notice; TD Cowen may also terminate on specified events (e.g., material adverse effect, regulatory trading suspension). The company may also not issue any shares under the agreement.

Why It Matters
This agreement gives Anteris a flexible way to raise capital as needed by selling shares into the market rather than through a single fixed-price offering. For investors, that means potential dilution if the company elects to issue shares under the program, and possible downward pressure on the stock if large amounts are sold into the market. At the same time, it provides the company with an on-demand financing tool to fund continued development of its DurAVR heart valve program and general operations. The filing does not guarantee that any shares will be sold.